{"organizations": [], "uuid": "3f7402b6508154d1ee43b2de776881c5ac530f2a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180226.html", "section_title": "Archive News &amp; Video for Monday, 26 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-achillion-announces-ach-4471-recei/brief-achillion-announces-ach-4471-receives-positive-opinion-for-orphan-drug-status-in-eu-for-the-treatment-of-c3-glomerulopathy-idUSFWN1QG0S8", "country": "US", "domain_rank": 408, "title": "BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.648, "site_type": "news", "published": "2018-02-26T19:31:00.000+02:00", "replies_count": 0, "uuid": "3f7402b6508154d1ee43b2de776881c5ac530f2a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-achillion-announces-ach-4471-recei/brief-achillion-announces-ach-4471-receives-positive-opinion-for-orphan-drug-status-in-eu-for-the-treatment-of-c3-glomerulopathy-idUSFWN1QG0S8", "ord_in_thread": 0, "title": "BRIEF-Achillion Announces ACH-4471 Receives Positive Opinion For Orphan Drug Status In EU For The Treatment Of C3 Glomerulopathy", "locations": [], "entities": {"persons": [], "locations": [{"name": "eu", "sentiment": "none"}, {"name": "european union", "sentiment": "none"}], "organizations": [{"name": "reuters) - achillion pharmaceuticals inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 26 (Reuters) - Achillion Pharmaceuticals Inc:\n* ACHILLION ANNOUNCES ACH-4471 RECEIVES POSITIVE OPINION FOR ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR THE TREATMENT OF C3 GLOMERULOPATHY\n* ACHILLION - ‍EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS ISSUED POSITIVE OPINION ON ACH-4471 FOR ORPHAN STATUS IN EU FOR C3 GLOMERULOPATHY​ TREATMENT Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-26T19:31:00.000+02:00", "crawled": "2018-02-27T14:54:12.034+02:00", "highlightTitle": ""}